Group 1 - The core viewpoint emphasizes the need for brands to redefine marketing effectiveness amidst intensified competition and evolving marketing forms [2] - Marketing is increasingly shifting online, with four typical industry marketing observations identified [2] - Key marketing focus areas for 2025 include connecting with users and improving efficiency, which are foundational to marketing strategies [2] Group 2 - Different investment strategies are observed across industries: 1) Automotive and small appliances show no increase in investment but focus on multi-dimensional innovation and structural adjustments [3] 2) Beauty industry maintains stable investment while enhancing channel integration [3] 3) Life services and sports apparel experience significant investment growth aimed at strong exposure [3] 4) New industries like AIGC are aggressively capturing market share [3]

4月10日15:00 营销流量再分配，营销效果重新定义如何聚焦？ 欢迎扫码预约，来直播间互动赢好礼 直播亮点： 1、营销流量重构，内容流量强化深度触达 2、品牌以用户为核心布局，营销与渠道进一步融合 3、2025营销重点继续连接用户和提高效率，三大关键点构成营销基础 直播亮点： 营销继续向线上迁移，四大典型类型行业营销观察： 1）投入不增，多元创新，结构调整，如：汽车、小家电 2）投入维稳，渠道融合增强，如：美妆 3）投入大幅增长，强曝光突破，如：生活服务、运动服饰 4）新行业营销抢市场，如：AIGC QuestMobile 2024年中国营销市场年度报告 行业篇 f争加剧、营销形态变 维挤压 ,品牌营 HE W 出車制? 4月11日15:00 竞争加剧、营销形态变革等多维挤压下，品牌营销如何突出重围？ 欢迎扫码预约，来直播间互动赢好礼 投入维稳,渠道融合增强,如:美妆 投入大幅增长,强曝光突破,如:生活服务、运动 服饰 新行业营销抢市场,如:AIGC 号兵:土 QuestMobile 高级研究经理 15:00-16:00 扫码预约 》》》》》》》》 the state 分享嘉兵:学 QuestMobile ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of e.l.f. Beauty, Inc. regarding a class action lawsuit due to alleged misleading statements and inflated financial reporting during a specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from November 1, 2023, to November 19, 2024 [3]. - Allegations include that e.l.f. Beauty issued materially false and misleading statements, failed to disclose rising inventory levels due to declining sales, and reported inflated revenue and profits to maintain investor confidence [3]. Impact on Company - The complaint suggests that the company's business and financial prospects were overstated, and the eventual revelation of these issues would likely have a material negative impact on the company [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by May 5, 2025, to potentially be appointed as lead plaintiffs and to receive updates on the case [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to the company's alleged deceitful practices [5].

Financial Performance - FY 2024 - Waldencast's Net Revenue reached $273.9 million, with a Comparable Net Revenue Growth of 27.5%[39] - The Adjusted Gross Profit was $203.6 million, representing a 74.3% Adjusted Gross Margin[39] - Adjusted EBITDA stood at $40.3 million, resulting in a 14.7% Adjusted EBITDA Margin[39] - Adjusted Free Cash Flow was $31.7 million, with an Adjusted EBITDA to Adjusted Free Cash Flow Conversion of 78.8%[41] Financial Performance - Q4 2024 - Net Revenue for Q4 2024 was $72.1 million, showing a 29.4% Comparable Net Revenue Growth[36] - Adjusted Gross Profit for Q4 reached $52.6 million, with a 73.0% Adjusted Gross Margin[36] - Adjusted EBITDA for Q4 was $11.2 million, resulting in a 15.5% Adjusted EBITDA Margin[36] Brand Performance - FY 2024 - Obagi Medical's Net Revenue was $149.3 million, with a Comparable Net Revenue Growth of 30.7% and an Adjusted EBITDA of $30.5 million[80] - Milk Makeup's Net Revenue was $124.6 million, with an Adjusted EBITDA of $29.1 million[80] Future Outlook - For FY 2025, the company anticipates mid-teens Net Revenue growth and mid-to-high teens Adjusted EBITDA Margin[45]

Financial Data and Key Metrics Changes - Net revenue for Q4 reached $72.1 million, a 29.4% increase year-over-year, with Milk Makeup growing 31.9% and Obagi Medical growing 27.7% [18][19] - For the full fiscal year, net revenue was $273.9 million, a 27.5% increase compared to the previous year [20] - Adjusted EBITDA for Q4 doubled to $11.2 million, with an adjusted EBITDA margin of 15.5%, reflecting strong revenue momentum [19][21] - Adjusted gross profit for the full year rose to $203.6 million, a 35.3% increase, with an adjusted gross profit margin of 74.3% [20][21] Business Line Data and Key Metrics Changes - Milk Makeup generated Q4 net revenue of $29.9 million, a 31.9% increase, with adjusted EBITDA rising to $4.8 million [28][30] - Obagi Medical achieved Q4 net revenue of $42.2 million, a 27.7% increase, with adjusted EBITDA of $9.8 million [38][39] - For the fiscal year, Milk Makeup's net revenue was $124.6 million, a 24% increase, while Obagi Medical's net revenue was $149.3 million, a 30.7% increase [30][39] Market Data and Key Metrics Changes - The prestige beauty market grew 7% in 2024, with professional skincare growing 8% and prestige makeup growing 5% [7][8] - The company noted that its brands are outperforming the market, with Milk Makeup growing five times faster than the overall beauty market rate [14][47] Company Strategy and Development Direction - The company aims to build a multi-brand platform encompassing various strategic categories and geographies, focusing on operational efficiency and brand equity [12][16] - The growth strategy for Milk Makeup includes expanding brand awareness, launching innovative products, and broadening distribution both online and offline [31][34] - Obagi Medical's strategy focuses on dermatological brand DNA, cutting-edge innovation, and increasing brand awareness to fuel growth [40][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of beauty consumers despite a changing macro environment, emphasizing premiumization trends [72] - The company anticipates strong performance in 2025, expecting mid-teens net revenue growth and further expansion of adjusted EBITDA margins [25][26] Other Important Information - The company secured a new $205 million credit facility, enhancing financial flexibility and extending debt maturity [24] - Cash position at the end of 2024 was $14.8 million, with an additional $30 million available on the revolving credit facility [23] Q&A Session Summary Question: Can you provide details on the cadence of innovation and confidence in sales acceleration? - Management highlighted that Q1's flat guidance is due to anniversary effects of previous successful launches and retail inventory adjustments, with expectations for strong sequential growth throughout the year [50][52][54] Question: What are the marketing strategies for the year? - Management plans to increase marketing investments, focusing on broader paid campaigns while maintaining organic growth strategies [61][63] Question: How is the macro environment affecting consumer health? - Management noted that the beauty industry remains resilient, with consumers continuing to spend on premium products despite some normalization in growth rates [70][72] Question: Will the Ulta launch affect Sephora sales? - Management confirmed that there is no loss of space at Sephora due to the Ulta launch, and the overall impact is expected to be incremental [88][90]

Financial Data and Key Metrics Changes - Total net revenues for Q4 2024 increased by 7.1% year-over-year to RMB 1.15 billion from RMB 1.07 billion in the prior year period [24] - Gross margin for Q4 2024 increased to 77.8% from 73.7% in the prior year period, driven by higher gross margin products [10][25] - For the full year 2024, total net revenues decreased by 0.6% year-over-year to RMB 3.39 billion from RMB 3.41 billion [34] - Net loss for the full year 2024 was RMB 710.2 million, a decrease from RMB 750.2 million in the prior year [36] Business Line Data and Key Metrics Changes - Combined revenues from clinical and premium skincare brands grew by 3% year-over-year, while color cosmetics revenues increased by 16.4% in Q4 2024 [9][10] - Skincare revenues grew by 0.7% year-over-year for the full year 2024, with skincare brands accounting for 41.1% of total net revenues [11] - Color cosmetics revenues saw a modest decline of 0.3% year-over-year for the full year 2024 [11] Market Data and Key Metrics Changes - The overall beauty retail sales in China declined by 1.5% year-over-year in Q4 2024, contrasting with total retail sales of consumer goods which grew by 3.8% [8] Company Strategy and Development Direction - The company is focusing on balancing revenue growth between skincare and color cosmetics, with skincare expected to be a stable growth engine [44][49] - Strategic initiatives include enhancing brand equity, refining product and channel mix, and investing in R&D for sustainable growth [13][18] - The company aims to improve operational efficiencies and strategically allocate resources for long-term growth [22] Management's Comments on Operating Environment and Future Outlook - Management noted that headwinds in the beauty market will persist, with intensified price competition and more rational consumer purchasing decisions [44] - The company expects total net revenues for Q1 2025 to be between RMB 788.8 million and RMB 866.2 million, reflecting a year-over-year increase of approximately 2% to 12% [38] Other Important Information - R&D expenses represented 3.2% of total net revenues for the full year 2024, highlighting the company's commitment to innovation [18] - The company achieved its lowest full-year net loss and non-GAAP net loss since 2020 [12] Q&A Session Summary Question: Future profitability expectations for 2025 and resource allocation between categories - Management acknowledged the positive Q4 performance and emphasized the importance of maintaining and improving gross margin growth while balancing growth and profitability [44] - Skincare is expected to remain a key stable growth engine, while color cosmetics, particularly Perfect Diary, are anticipated to contribute to sustainable growth [45][49]